Form4insider filings, from the source

SEC Form 4 · accession 0001209191-18-043394

IMMUNE DESIGN CORP. · IMDZ

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner
Jan Henrik ter Meulen
Officer — Chief Scientific Officer
Period of report
Jul 17, 2018
Accepted (ET)
Jul 19, 2018 · 6:02 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001437786

Table I — non-derivative securities

No Table I lines on this filing.

Table II — derivative securities

SecurityConv. / exercise priceDateCodeSharesA/DExercisableExpiresUnderlyingUnderlying sharesOwned afterD/I
Stock Option (Rt to Buy)F2,F1$31.00Jul 17, 2018D2,493D—Jan 7, 2025Common Stock2,4930D
Stock Option (Rt to Buy)F2,F3$4.40Jul 17, 2018A1,247A—Jul 17, 2025Common Stock1,2471,247D
Stock Option (Rt to Buy)F4,F1$31.00Jul 17, 2018D22,507D—Jan 7, 2025Common Stock22,5070D
Stock Option (Rt to Buy)F4,F3$4.40Jul 17, 2018A11,254A—Jul 17, 2025Common Stock11,25411,254D
Stock Option (Rt to Buy)F6,F5$19.39Jul 17, 2018D5,574D—Jan 4, 2026Common Stock5,5740D
Stock Option (rt to Buy)F6,F3$4.40Jul 17, 2018A3,186A—Jul 17, 2025Common Stock3,1863,186D
Stock Option (Rt to Buy)F7,F5$19.39Jul 17, 2018D54,426D—Jan 4, 2026Common Stock54,4260D
Stock Option (Rt to Buy)F7,F3$4.40Jul 17, 2018A31,101A—Jul 17, 2025Common Stock31,10131,101D

Explanation of responses